RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary from the author on Twitter (thread – click for more)

My first Tweetorial ? 2 year toxicity results of PACE B published here. Big thanks to the ???? and??collaborators and the 874 men with prostate cancer who made this trial possible https://t.co/mERz2ox8TM

— Alison Tree ??? (@alison_tree) September 14, 2022